Syndax Announces Clinical Data from its Entinostat Immuno-oncology Program Selected for Two Oral Presentations at the American Association for Cancer Research Annual Meeting 2019

[In The News]

WALTHAM, Mass., Feb. 27, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced two oral presentations at the upcoming American...

View the full article